Gian Marco Leone

1 Introduction Burkitt lymphoma (BL) is an aggressive mature B-cell neoplasm. Characterized by uniform, medium-sized cells with basophilic cytoplasm, multiple small nucleoli, a germinal center B-cell immunophenotype, a high proliferation rate, and MYC rearrangement involving an immunoglobulin (Ig) gene partner [1]. Additional but not consistently present features of BL include a diffuse growth pattern and a characteristic starry-sky appearance.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Abstract : Lung cancer (LC) represents the second most diagnosed tumor and the malignancy with the highest mortality rate. In recent years, tremendous progress has been made in the treatment of this tumor thanks to the discovery, testing, and clinical approval of novel therapeutic approaches. Firstly, targeted therapies aimed at inhibiting specific mutated tyrosine kinases or downstream factors were approved in clinical practice.